Literature DB >> 28574202

Adaptive power priors with empirical Bayes for clinical trials.

Isaac Gravestock1, Leonhard Held1.   

Abstract

Incorporating historical information into the design and analysis of a new clinical trial has been the subject of much discussion as a way to increase the feasibility of trials in situations where patients are difficult to recruit. The best method to include this data is not yet clear, especially in the case when few historical studies are available. This paper looks at the power prior technique afresh in a binomial setting and examines some previously unexamined properties, such as Box P values, bias, and coverage. Additionally, it proposes an empirical Bayes-type approach to estimating the prior weight parameter by marginal likelihood. This estimate has advantages over previously criticised methods in that it varies commensurably with differences in the historical and current data and can choose weights near 1 when the data are similar enough. Fully Bayesian approaches are also considered. An analysis of the operating characteristics shows that the adaptive methods work well and that the various approaches have different strengths and weaknesses.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian; clinical trials; empirical Bayes; historical data; power prior

Mesh:

Year:  2017        PMID: 28574202     DOI: 10.1002/pst.1814

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  10 in total

1.  Machine Learning for Supplementing Behavioral Assessment.

Authors:  Jordan D Bailey; Jonathan C Baker; Mark J Rzeszutek; Marc J Lanovaz
Journal:  Perspect Behav Sci       Date:  2021-01-09

2.  New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.

Authors:  Samiran Ghosh; Erina Paul; Shrabanti Chowdhury; Ram C Tiwari
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

3.  Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.

Authors:  Caroline Brard; Lisa V Hampson; Nathalie Gaspar; Marie-Cécile Le Deley; Gwénaël Le Teuff
Journal:  BMC Med Res Methodol       Date:  2019-04-24       Impact factor: 4.615

4.  Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control.

Authors:  Annette Kopp-Schneider; Silvia Calderazzo; Manuel Wiesenfarth
Journal:  Biom J       Date:  2019-07-02       Impact factor: 2.207

5.  An adaptive power prior for sequential clinical trials - Application to bridging studies.

Authors:  Adrien Ollier; Satoshi Morita; Moreno Ursino; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2019-11-15       Impact factor: 3.021

6.  Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.

Authors:  Hongchao Qi; Dimitris Rizopoulos; Emmanuel Lesaffre; Joost van Rosmalen
Journal:  Pharm Stat       Date:  2022-02-06       Impact factor: 1.234

7.  A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.

Authors:  Silvia Calderazzo; Manuel Wiesenfarth; Annette Kopp-Schneider
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.279

8.  Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Authors:  Marlieke E A de Kraker; Harriet Sommer; Femke de Velde; Isaac Gravestock; Emmanuel Weiss; Alexandra McAleenan; Stavros Nikolakopoulos; Ohad Amit; Teri Ashton; Jan Beyersmann; Leonhard Held; Andrew M Lovering; Alasdair P MacGowan; Johan W Mouton; Jean-François Timsit; David Wilson; Martin Wolkewitz; Esther Bettiol; Aaron Dane; Stephan Harbarth
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

9.  Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.

Authors:  Andrea Bassi; Johannes Berkhof; Daphne de Jong; Peter M van de Ven
Journal:  Stat Methods Med Res       Date:  2020-11-26       Impact factor: 3.021

10.  Combined assessment of early and late-phase outcomes in orphan drug development.

Authors:  Konstantinos Pateras; Stavros Nikolakopoulos; Kit C B Roes
Journal:  Stat Med       Date:  2021-04-04       Impact factor: 2.373

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.